In Tuesday’s Wall Street session, Verve Therapeutics Inc (NASDAQ:VERV) shares traded at $4.97, up 20.63% from the previous session.
VERV stock price is now -17.69% away from the 50-day moving average and -15.77% away from the 200-day moving average. The market capitalization of the company currently stands at $441.32M.
On April 08, 2024, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $15, while ‘Canaccord Genuity’ rates the stock as ‘Buy’
In other news, Kathiresan Sekar, Chief Executive Officer sold 9,822 shares of the company’s stock on Apr 02 ’25. The stock was sold for $40,761 at an average price of $4.15. Upon completion of the transaction, the Chief Executive Officer now directly owns 346,686 shares in the company, valued at $1.72 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 02 ’25, Chief Administrative Officer Nickerson Joan sold 2,777 shares of the business’s stock. A total of $11,525 was realized by selling the stock at an average price of $4.15. This leaves the insider owning 17,420 shares of the company worth $86577.4. A total of 25.54% of the company’s stock is owned by insiders.
During the past 12 months, Verve Therapeutics Inc has had a low of $2.86 and a high of $9.31. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 12.65, and a quick ratio of 12.65. The fifty day moving average price for VERV is $6.0383 and a two-hundred day moving average price translates $5.9006 for the stock.
The latest earnings results from Verve Therapeutics Inc (NASDAQ: VERV) was released for 2024-12-31. The net profit margin was -614.59% and return on equity was -36.36% for VERV. The company reported revenue of $13.08 million for the quarter, compared to $5.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 154.28 percent. For the current quarter, analysts expect VERV to generate $9.38M in revenue.
